EA Policies for Single Patient
On our website (www.nuvectis.com) physicians and patients may explore information about our investigational drug candidate, NXP800.
Given the early stage of the NXP800 development program, we believe that participation in our clinical trial(s) is the most appropriate way to access NXP800, and therefore we are currently not making NXP800 available through an expanded access program.
In line with the 21st Century Cures Act, Nuvectis may revise this policy at any time.